Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
47.31
-0.28 (-0.59%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
61
62
Next >
Gold Moves Higher; US Consumer Sentiment Improves In December
December 22, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
With Karuna Therapeutics $14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst
December 22, 2023
Earlier Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 bill
Via
Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) Making Surprising Moves in Friday Session
December 22, 2023
Via
Investor Brand Network
Exposures
COVID-19
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
December 22, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
December 15, 2023
Via
Benzinga
Is Bristol Myers Squibb Stock a Buy Now?
December 15, 2023
The answer might depend on the kind of investor you are.
Via
The Motley Fool
Is NYSE:BMY a Good Fit for Dividend Investing?
December 14, 2023
Balancing Dividends and Fundamentals: The Case of BRISTOL-MYERS SQUIBB CO (NYSE:BMY).
Via
Chartmill
Health Care Company Bristol-Myers Squibb Announces Merger With Karuna Therapeutics
December 22, 2023
Via
Benzinga
Dow Rises 50 Points; Fed's Preferred Inflation Gauge Cools In November
December 22, 2023
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Bristol Myers Squibb Scoops Up Schizophrenia Player Karuna Therapeutics In Massive $14B Deal
December 22, 2023
On Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion n
Via
Benzinga
Karuna Stock Soars On Bristol Myers' $14 Billion Takeover
December 22, 2023
Karuna is working on treatments for schizophrenia and Alzheimer's disease psychosis.
Via
Investor's Business Daily
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
December 22, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
December 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
December 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
3 Potential Turnaround Stocks to Buy for Big Rewards in 2024
December 20, 2023
There was plenty to get excited about in 2023 and even more to get excited about with turnaround stocks in the new year.
Via
InvestorPlace
Better Dividend Stock: Bristol Myers Squibb or Merck?
December 19, 2023
These two pharma stocks have sizable dividend yields. Which is the better buy right now?
Via
The Motley Fool
Jim Cramer Slams FTC Chair Lina Khan's Policies For Hampering Investor Returns: 'One-Woman Wrecking Crew For Your Stock Portfolio'
December 18, 2023
He posits that such actions have negatively impacted stock valuations.
Via
Benzinga
7 Stocks with Strong Insider Buying: December 2023
December 17, 2023
Here are just a few of the top stocks with strong insider buying that all investors may want to watch heading into 2024.
Via
InvestorPlace
Week in Review: SystImmune Out-Licenses Global Rights for ADC to BMS in $8.4 Billion Deal
December 16, 2023
SystImmune, the Seattle arm of Chengdu’s Biokin Pharma, out-licensed global rights (ex-China) for a bispecific ADC to Bristol Myers Squibb in a $8.4 billion agreement.
Via
Talk Markets
Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
December 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
December 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
December 12, 2023
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)
Via
Benzinga
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
December 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
Regulators are already on the case, and their findings will have financial impacts.
Via
The Motley Fool
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
December 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
3 Dividend Stocks Trading at 52-Week Lows
December 09, 2023
All three of these companies have seen brighter days.
Via
The Motley Fool
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
61
62
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.